Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
Tracy Cole, Hien Zhao, Timothy J. Collier, et al.
JCI Insight (2021) Vol. 6, Iss. 5
Open Access | Times Cited: 94

Showing 26-50 of 94 citing articles:

Pathways to healing: Plants with therapeutic potential for neurodegenerative diseases
Sheena E.B. Tyler, Luke D.K. Tyler
IBRO Neuroscience Reports (2023) Vol. 14, pp. 210-234
Open Access | Times Cited: 16
Small molecule modulators of Alpha-Synuclein Aggregation and Toxicity: Pioneering an Emerging Arsenal Against Parkinson’s Disease
Ishfaq Ahmad Ahanger, Tanveer Ali Dar
Ageing Research Reviews (2024) Vol. 101, pp. 102538-102538
Closed Access | Times Cited: 5
Biomimetic nanodecoys deliver cholesterol-modified heteroduplex oligonucleotide to target dopaminergic neurons for the treatment of Parkinson's disease
Si Huang, Yongjiang Li, Junyong Wu, et al.
Acta Biomaterialia (2024) Vol. 177, pp. 316-331
Open Access | Times Cited: 4
Effective lowering of α-synuclein expression by targeting G-quadruplex structures within the SNCA gene
Valentina Pirota, Federica Rey, Letizia Esposito, et al.
International Journal of Biological Macromolecules (2024) Vol. 277, pp. 134417-134417
Open Access | Times Cited: 4
α-Synuclein pathology as a target in neurodegenerative diseases
Hye-Jin Park, Tae‐In Kam, Valina L. Dawson, et al.
Nature Reviews Neurology (2024)
Closed Access | Times Cited: 4
Regenerative Strategies for Parkinson’s Disease
Thomas B. Stoker, Daniela Noaín
Cambridge University Press eBooks (2025), pp. 252-263
Closed Access
La maladie de Parkinson : de la génétique aux thérapies ciblées
Guillaume Cogan, Alexis Brice
Comptes Rendus Biologies (2025) Vol. 348, Iss. G1, pp. 21-33
Open Access
A personalised and comprehensive approach is required to suppress or replenish SNCA for Parkinson’s disease
Dunhui Li, Wai Yan Yau, Shengdi Chen, et al.
npj Parkinson s Disease (2025) Vol. 11, Iss. 1
Open Access
Oligonucleotide-Based Therapeutics for Neurodegenerative Disorders: Focus on Antisense Oligonucleotides
Heba M. Mansour, Aiman S. El‐Khatib
European Journal of Pharmacology (2025), pp. 177529-177529
Closed Access
Peptidomimetics Activating the Proteasome: A New Perspective for Parkinson’s Treatment
Karolina Trepczyk, Şafak Er, Irena Hlushchuk, et al.
Journal of Medicinal Chemistry (2025)
Open Access
RNA‐Based Therapies for Neurodegenerative Diseases Targeting Pathogenic Proteins
Syed Arman Rabbani, Mohamed El‐Tanani, Shrestha Sharma, et al.
European Journal of Neuroscience (2025) Vol. 61, Iss. 8
Closed Access
Advanced gene therapy in Parkinson’s disease through innovations in drug delivery systems
Nguyễn Phương Thảo, Thuy-vi Nguyen, Soyeun Park
Journal of Pharmaceutical Investigation (2025)
Closed Access
Alpha-synuclein pathology and Parkinson’s disease-related olfactory dysfunctions: an update on preclinical models and therapeutic approaches
Jancy Nixon Abraham, Dinesh Rawat, Priyadharshini Srikanth, et al.
Mammalian Genome (2025)
Open Access
Fibril-seeded animal models of synucleinopathies: pathological mechanisms, disease modeling, and therapeutic implications
Norihito Uemura
Neuroscience Research (2025)
Open Access
The Future of Targeted Gene-Based Treatment Strategies and Biomarkers in Parkinson’s Disease
Alexia Polissidis, Lilian Petropoulou-Vathi, Modestos Nakos‐Bimpos, et al.
Biomolecules (2020) Vol. 10, Iss. 6, pp. 912-912
Open Access | Times Cited: 31
Interleukin 22 and its association with neurodegenerative disease activity
Wenjian Chen, Jianpeng Wang, Huaizhi Yang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 18
Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?
Victoria Sidoroff, Pam Bower, Nadia Stefanova, et al.
Journal of Parkinson s Disease (2022) Vol. 12, Iss. 5, pp. 1369-1387
Open Access | Times Cited: 17
Effects of local reduction of endogenous α-synuclein using antisense oligonucleotides on the fibril-induced propagation of pathology through the neural network in wild-type mice
Tatsuhiko Sano, Tetsuya Nagata, Satoe Ebihara, et al.
Acta Neuropathologica Communications (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 3
Functions of Intracellular Alpha-Synuclein in Microglia: Implications for Parkinson’s Disease Risk
Alix Booms, Gerhard A. Coetzee
Frontiers in Cellular Neuroscience (2021) Vol. 15
Open Access | Times Cited: 23
Targeted protein degradation using intracellular antibodies and its application to neurodegenerative disease
Jonathan Benn, Aamir S. Mukadam, William A. McEwan
Seminars in Cell and Developmental Biology (2021) Vol. 126, pp. 138-149
Closed Access | Times Cited: 22
Synucleinopathy in Amyotrophic Lateral Sclerosis: A Potential Avenue for Antisense Therapeutics?
Bradley Roberts, Frances Theunissen, Francis Mastaglia, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 16, pp. 9364-9364
Open Access | Times Cited: 15
Antisense therapy: a potential breakthrough in the treatment of neurodegenerative diseases
Roberta Romanò, Cecilia Bucci
Neural Regeneration Research (2023) Vol. 19, Iss. 5, pp. 1027-1035
Open Access | Times Cited: 9
Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research
Mohammad Ahmed Khan, Nafis Haider, Tanveer Singh, et al.
Metabolic Brain Disease (2023) Vol. 38, Iss. 3, pp. 873-919
Closed Access | Times Cited: 8
Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s disease
Jillian H. Kluss, Patrick A. Lewis, Elisa Greggio
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 6, pp. 537-546
Open Access | Times Cited: 13
Gene specific therapies – the next therapeutic milestone in neurology
Dávid Brenner, Albert C. Ludolph, Jochen H. Weishaupt
Neurological Research and Practice (2020) Vol. 2, Iss. 1
Open Access | Times Cited: 19

Scroll to top